BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
07 Giugno 2024 - 1:00PM
BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular
and cell-derived therapeutics for the treatment of cardiovascular
and pulmonary diseases, today announces that the Unites States
Patent Office has granted Patent No: 11,986,611 titled “Radial and
Transendocardial Delivery Catheter,” with a patent term that will
expire in 2036.
The present invention relates to medical methods and systems
suitable for substance delivery to the heart via a radial artery
and for the intracardiac delivery of cellular aggregates and other
agglomerated materials.
Radial artery delivery is a means by which cardiac catheters are
advanced through a blood vessel in a patient’s wrist to treat the
heart. This approach has significant advantages for patients,
enabling them to leave the hospital soon after the procedure with a
band aid on their wrist and their arm in a simple sling, allowing
them to immediately return to their active lives. In addition, a
radial approach permits hospitals and other care centers to greatly
reduce costs by eliminating the need for an overnight stay by the
patient. For these reasons, trans-radial access is becoming the
default approach in many cardiac centers worldwide. Enabling radial
access has enormous potential advantages for biotherapeutic
delivery to the heart.
BioCardia’s Helix system, used in our ongoing clinical trials,
is the only known system with patented designs that can enable
radial transendocardial biotherapeutic delivery. The issued patent
claims further protect this approach and add value to both
BioCardia’s therapeutic programs and those of our biotherapeutic
delivery partners.
Therapeutic cell aggregates have the potential advantage over
single cell suspensions by enhancing retention in the heart to
maximize therapeutic benefit. However, the delivery of cell
aggregates carries greater risks of potentially life-threatening
strokes should they leak into the ventricular chamber. As 20% of
the blood in the heart chamber goes to the brain, 20% of any cell
or cell aggregates released in the heart are expected to obstruct
the first cerebral artery that is too small to allow the cell or
cell aggregate to pass. The larger the cell aggregate, the larger
the vessel they are capable of obstructing, with greater risk of a
significant life-threatening stroke.
BioCardia’s delivery systems are designed to prevent leakage of
therapeutic agents into the ventricular chamber by providing stable
and safe engagement to the heart tissue during the delivery
process. The issued patent claims further protect this design and
add value to both BioCardia’s therapeutic programs and those of our
biotherapeutic delivery partners.
“Our minimally invasive biotherapeutic delivery platforms enable
the successful development of cell and gene-based therapies for the
heart,” said Dr. Peter Altman, BioCardia CEO. “The Helix platform
underlies BioCardia’s cell therapy clinical programs and this
recent patent issuance provides additional protection to our
technology and product offerings in the United States for at least
another dozen years. This is just one of many patent applications
we are advancing to protect our value creation for the benefit of
shareholders, which in turn enables these advances to be supported
for expected benefit to millions of patients.”
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is
developing cellular and cell-derived therapeutics for the treatment
of cardiovascular and pulmonary diseases. CardiAMP™ autologous and
CardiALLO allogeneic cell therapies are the Company’s
biotherapeutic platforms in three clinical stage product candidates
in development. BioCardia also partners with other biotherapeutic
companies to provide its delivery systems and development support
to their programs. For more information
visit: www.BioCardia.com.
Forward Looking Statements:
This press release contains forward-looking statements that are
subject to many risks and uncertainties. Forward-looking statements
include, among other things, references to the Company’s
investigational product candidates, the benefits and risks of cell
aggregates, the benefits of radial artery access, the level and
duration of patent protection that the Company’s patents provide to
its product candidates, and the expected safety of BioCardia’s
delivery device designs. These forward-looking statements are made
as of the date of this press release, and BioCardia assumes no
obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” “approximately” or other words that convey the
uncertainty of future events or outcomes to identify these
forward-looking statements. Although we believe that we have a
reasonable basis for each forward-looking statement contained
herein, we caution you that forward-looking statements are not
guarantees of future performance and that our actual results may
differ materially from the forward-looking statements contained in
this press release. As a result of these factors, we cannot assure
you that the forward-looking statements in this press release will
prove to be accurate. Additional factors that could materially
affect actual results can be found in BioCardia’s Form 10-K filed
with the Securities and Exchange Commission on March 27, 2024,
under the caption titled “Risk Factors” And in its subsequently
filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
Media Contact:
Miranda Peto, Marketing / Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120
Grafico Azioni BioCardia (NASDAQ:BCDA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni BioCardia (NASDAQ:BCDA)
Storico
Da Giu 2023 a Giu 2024